The Epigenetics (R)evolution
This article was originally published in Start Up
Constellation and EpiZyme are poised to become dominant players in the unfolding field of epigenetics, an area of biology replete with novel, interesting targets and broad therapeutic potential. The two companies have adopted similar and until now stealthy strategies, aimed at parlaying a platform of novel products into a quick and lucrative exit.
You may also be interested in...
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
Epigenetics, an area of biology replete with interesting novel targets and potential for developing drugs that overcome cancer resistance, is a popular topic this year at the American Association for Cancer Research annual meeting, in Washington, D.C., April 6-10.
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.